{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:46:48Z","timestamp":1789591608464,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018784","name":"Foundation of Hope for Research and Treatment of Mental Illness","doi-asserted-by":"publisher","award":["Foundation of Hope for Research and Treatment of Mental Illness"],"award-info":[{"award-number":["Foundation of Hope for Research and Treatment of Mental Illness"]}],"id":[{"id":"10.13039\/100018784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016651","name":"Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill"],"award-info":[{"award-number":["Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill"]}],"id":[{"id":"10.13039\/100016651","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00213-025-06854-3","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T07:05:45Z","timestamp":1753254345000},"page":"1185-1197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats"],"prefix":"10.1007","volume":"243","author":[{"given":"McKinley","family":"Windram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis F.","family":"Lovelock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Carew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline G.","family":"Krieman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian S.","family":"Hendershot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-8376","authenticated-orcid":false,"given":"Joyce","family":"Besheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"6854_CR1","doi-asserted-by":"crossref","unstructured":"Aran\u00e4s C, Edvardsson CE, Shevchouk OT et al (2023) Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine 93:104642","DOI":"10.1016\/j.ebiom.2023.104642"},{"key":"6854_CR2","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/bph.17406","volume":"182","author":"C Aran\u00e4s","year":"2025","unstructured":"Aran\u00e4s C, Caffrey A, Edvardsson CE et al (2025) Synergistic-like decreases in alcohol intake following combined pharmacotherapy with GLP-1 and Amylin in male rats. Br J Pharmacol 182:1292\u20131305","journal-title":"Br J Pharmacol"},{"key":"6854_CR3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/brainsci13111503","volume":"13","author":"D Arillotta","year":"2023","unstructured":"Arillotta D, Floresta G, Guirguis A et al (2023) GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach. Brain Sci 13:1503","journal-title":"Brain Sci"},{"key":"6854_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/brainsci14060617","volume":"14","author":"D Arillotta","year":"2024","unstructured":"Arillotta D, Floresta G, Papanti Pelletier GD et al (2024) Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach. Brain Sci 14:617","journal-title":"Brain Sci"},{"key":"6854_CR5","doi-asserted-by":"crossref","unstructured":"Badulescu S, Tabassum A, Le GH et al (2024) Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review. Physiol Behav 283:114622","DOI":"10.1016\/j.physbeh.2024.114622"},{"key":"6854_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/sj.npp.1300616","volume":"30","author":"J Besheer","year":"2005","unstructured":"Besheer J, Hodge CW (2005) Pharmacological and anatomical evidence for an interaction between mGluR5-and GABAA \u03b11-containing receptors in the discriminative stimulus effects of ethanol. Neuropsychopharmacology 30:747\u2013757","journal-title":"Neuropsychopharmacology"},{"key":"6854_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1037\/pha0000077","volume":"24","author":"BL Bolin","year":"2016","unstructured":"Bolin BL, Alcorn JL III, Reynolds AR et al (2016) Human drug discrimination: A primer and methodological review. Exp Clin Psychopharmacol 24:214","journal-title":"Exp Clin Psychopharmacol"},{"key":"6854_CR8","first-page":"5","volume":"85","author":"MP Bremmer","year":"2024","unstructured":"Bremmer MP, Hendershot CS (2024) Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders. J Stud Alcohol Drugs 85:5\u201310","journal-title":"J Stud Alcohol Drugs"},{"key":"6854_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.physbeh.2019.03.029","volume":"206","author":"A Brunchmann","year":"2019","unstructured":"Brunchmann A, Thomsen M, Fink-Jensen A (2019) The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review. Physiol Behav 206:232\u2013242","journal-title":"Physiol Behav"},{"key":"6854_CR10","doi-asserted-by":"crossref","unstructured":"Bruns VN, Tressler EH, Vendruscolo LF et al (2024) IUPHAR review-Glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target. Pharmacol Res 207:107312","DOI":"10.1016\/j.phrs.2024.107312"},{"key":"6854_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","volume":"33","author":"AM Chao","year":"2023","unstructured":"Chao AM, Tronieri JS, Amaro A, Wadden TA (2023) Semaglutide for the treatment of obesity. Trends Cardiovasc Med 33:159\u2013166","journal-title":"Trends Cardiovasc Med"},{"key":"6854_CR12","doi-asserted-by":"publisher","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","volume":"8","author":"V Chuong","year":"2023","unstructured":"Chuong V, Farokhnia M, Khom S et al (2023) The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight 8:e170671","journal-title":"JCI Insight"},{"key":"6854_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1021\/acschemneuro.4c00729","volume":"16","author":"P Delvadia","year":"2025","unstructured":"Delvadia P, Dhote V, Mandloi AS et al (2025) Dual GLP-1 and GIP agonist Tirzepatide exerted neuroprotective action in a parkinson\u2019s disease rat model. ACS Chem Neurosci 16:818\u2013825","journal-title":"ACS Chem Neurosci"},{"key":"6854_CR14","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","volume":"32","author":"SL Dickson","year":"2012","unstructured":"Dickson SL, Shirazi RH, Hansson C et al (2012) The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci 32:4812\u20134820","journal-title":"J Neurosci"},{"key":"6854_CR15","doi-asserted-by":"publisher","first-page":"14453","DOI":"10.1523\/JNEUROSCI.3262-11.2011","volume":"31","author":"AM Dossat","year":"2011","unstructured":"Dossat AM, Lilly N, Kay K, Williams DL (2011) Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J Neurosci 31:14453\u201314457","journal-title":"J Neurosci"},{"key":"6854_CR16","doi-asserted-by":"publisher","first-page":"e69010","DOI":"10.1371\/journal.pone.0069010","volume":"8","author":"E Egecioglu","year":"2013","unstructured":"Egecioglu E, Engel JA, Jerlhag E (2013) The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS ONE 8:e69010","journal-title":"PLoS ONE"},{"key":"6854_CR17","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/nm.3009","volume":"18","author":"B Finan","year":"2012","unstructured":"Finan B, Yang B, Ottaway N et al (2012) Targeted Estrogen delivery reverses the metabolic syndrome. Nat Med 18:1847\u20131856","journal-title":"Nat Med"},{"key":"6854_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/08039488.2016.1176252","volume":"70","author":"A Fink-Jensen","year":"2016","unstructured":"Fink-Jensen A, Vilsb\u00f8ll T (2016) Glucagon-like peptide-1 (GLP-1) analogues: A potential new treatment for alcohol use disorder? Nord J Psychiatry 70:561\u2013562","journal-title":"Nord J Psychiatry"},{"key":"6854_CR19","doi-asserted-by":"crossref","unstructured":"Fink-Jensen A, W\u00f6rtwein G, Klausen MK et al (2024) Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male Vervet monkeys. Psychopharmacology 242:1\u20138","DOI":"10.1007\/s00213-024-06637-2"},{"key":"6854_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/dom.14843","volume":"25","author":"CE Geisler","year":"2023","unstructured":"Geisler CE, Antonellis MP, Trumbauer W et al (2023) Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents. Diabetes Obes Metabolism 25:56\u201367","journal-title":"Diabetes Obes Metabolism"},{"key":"6854_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.pharmthera.2003.08.004","volume":"100","author":"KA Grant","year":"2003","unstructured":"Grant KA, Bennett AJ (2003) Advances in nonhuman primate alcohol abuse and alcoholism research. Pharmacol Ther 100:235\u2013255","journal-title":"Pharmacol Ther"},{"key":"6854_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cobeha.2016.02.005","volume":"9","author":"MR Hayes","year":"2016","unstructured":"Hayes MR, Schmidt HD (2016) GLP-1 influences food and drug reward. Curr Opin Behav Sci 9:66\u201370","journal-title":"Curr Opin Behav Sci"},{"key":"6854_CR23","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1210\/en.2007-1743","volume":"149","author":"MR Hayes","year":"2008","unstructured":"Hayes MR, Skibicka KP, Grill HJ (2008) Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149:4059\u20134068","journal-title":"Endocrinology"},{"key":"6854_CR24","doi-asserted-by":"crossref","unstructured":"Heilig M, Witkiewitz K, Ray LA et al (2024) Novel medications for problematic alcohol use. J Clin Invest 134:e172889","DOI":"10.1172\/JCI172889"},{"key":"6854_CR25","doi-asserted-by":"crossref","unstructured":"Hendershot CS, Bremmer MP, Paladino MB et al (2025) Once-Weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry","DOI":"10.1001\/jamapsychiatry.2024.4789"},{"key":"6854_CR26","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1111\/ejn.13374","volume":"44","author":"AA Jaramillo","year":"2016","unstructured":"Jaramillo AA, Randall PA, Frisbee S, Besheer J (2016) Modulation of sensitivity to alcohol by cortical and thalamic brain regions. Eur J Neurosci 44:2569\u20132580","journal-title":"Eur J Neurosci"},{"key":"6854_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuropharm.2017.11.035","volume":"130","author":"AA Jaramillo","year":"2018","unstructured":"Jaramillo AA, Randall PA, Stewart S et al (2018a) Functional role for cortical-striatal circuitry in modulating alcohol self-administration. Neuropharmacology 130:42\u201353. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.11.035","journal-title":"Neuropharmacology"},{"key":"6854_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bbr.2018.04.007","volume":"348","author":"AA Jaramillo","year":"2018","unstructured":"Jaramillo AA, Van Voorhies K, Randall PA, Besheer J (2018b) Silencing the insular-striatal circuit decreases alcohol self-administration and increases sensitivity to alcohol. Behav Brain Res 348:74\u201381","journal-title":"Behav Brain Res"},{"key":"6854_CR29","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP et al (2023) Triple\u2013hormone-receptor agonist Retatrutide for obesity\u2014a phase 2 trial. N Engl J Med 389:514\u2013526","journal-title":"N Engl J Med"},{"key":"6854_CR30","doi-asserted-by":"publisher","first-page":"1063033","DOI":"10.3389\/fphar.2023.1063033","volume":"14","author":"E Jerlhag","year":"2023","unstructured":"Jerlhag E (2023) The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol 14:1063033","journal-title":"Front Pharmacol"},{"key":"6854_CR31","doi-asserted-by":"publisher","first-page":"bqaf028","DOI":"10.1210\/endocr\/bqaf028","volume":"166","author":"E Jerlhag","year":"2025","unstructured":"Jerlhag E (2025) GLP-1 receptor agonists: promising therapeutic targets for alcohol use disorder. Endocrinology 166:bqaf028","journal-title":"Endocrinology"},{"key":"6854_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00228-024-03646-0","volume":"80","author":"M Kaur","year":"2024","unstructured":"Kaur M, Misra S (2024) A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol 80:669\u2013676","journal-title":"Eur J Clin Pharmacol"},{"key":"6854_CR33","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.biopsych.2013.08.001","volume":"75","author":"AC King","year":"2014","unstructured":"King AC, McNamara PJ, Hasin DS, Cao D (2014) Alcohol challenge responses predict future alcohol use disorder symptoms: a 6-year prospective study. Biol Psychiatry 75:798\u2013806","journal-title":"Biol Psychiatry"},{"key":"6854_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.biopsych.2015.05.007","volume":"79","author":"AC King","year":"2016","unstructured":"King AC, Hasin D, O\u2019Connor SJ et al (2016) A prospective 5-year re-examination of alcohol response in heavy drinkers progressing in alcohol use disorder. Biol Psychiatry 79:489\u2013498","journal-title":"Biol Psychiatry"},{"key":"6854_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bph.15677","volume":"179","author":"MK Klausen","year":"2022","unstructured":"Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A (2022) The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol 179:625\u2013641","journal-title":"Br J Pharmacol"},{"key":"6854_CR36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/npp.2009.110","volume":"35","author":"GF Koob","year":"2010","unstructured":"Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217\u2013238","journal-title":"Neuropsychopharmacology"},{"key":"6854_CR37","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nrd2828","volume":"8","author":"GF Koob","year":"2009","unstructured":"Koob GF, Kenneth Lloyd G, Mason BJ (2009) Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov 8:500\u2013515","journal-title":"Nat Rev Drug Discov"},{"key":"6854_CR38","doi-asserted-by":"publisher","first-page":"103925","DOI":"10.1016\/j.nsa.2023.103925","volume":"3","author":"KL Kooij","year":"2024","unstructured":"Kooij KL, Koster DIj, Eeltink E et al (2024) GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurosci Appl 3:103925","journal-title":"Neurosci Appl"},{"key":"6854_CR39","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","volume":"29","author":"L Leggio","year":"2023","unstructured":"Leggio L, Hendershot CS, Farokhnia M et al (2023) GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med 29:2993\u20132995","journal-title":"Nat Med"},{"key":"6854_CR40","doi-asserted-by":"publisher","first-page":"108807","DOI":"10.1016\/j.neuropharm.2021.108807","volume":"200","author":"DF Lovelock","year":"2021","unstructured":"Lovelock DF, Tyler RE, Besheer J (2021) Interoception and alcohol: mechanisms, networks, and implications. Neuropharmacology 200:108807","journal-title":"Neuropharmacology"},{"key":"6854_CR41","doi-asserted-by":"publisher","first-page":"599646","DOI":"10.3389\/fnins.2020.599646","volume":"14","author":"VN Marty","year":"2020","unstructured":"Marty VN, Farokhnia M, Munier JJ et al (2020) Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats. Front Neurosci 14:599646","journal-title":"Front Neurosci"},{"key":"6854_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","volume":"15","author":"A Meloni","year":"2013","unstructured":"Meloni A, DeYoung M, Lowe C, Parkes D (2013) GLP-1 receptor activated insulin secretion from pancreatic \u03b2-cells: mechanism and glucose dependence. Diabetes Obes Metabolism 15:15\u201327","journal-title":"Diabetes Obes Metabolism"},{"key":"6854_CR43","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","volume":"403","author":"I Merchenthaler","year":"1999","unstructured":"Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261\u2013280","journal-title":"J Comp Neurol"},{"key":"6854_CR44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1530-0277.2009.01103.x","volume":"34","author":"ME Morean","year":"2010","unstructured":"Morean ME, Corbin WR (2010) Subjective response to alcohol: a critical review of the literature. Alcohol Clin Exp Res 34:385\u2013395","journal-title":"Alcohol Clin Exp Res"},{"key":"6854_CR45","doi-asserted-by":"publisher","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","volume":"13","author":"F Quddos","year":"2023","unstructured":"Quddos F, Hubshman Z, Tegge A et al (2023) Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep 13:20998","journal-title":"Sci Rep"},{"key":"6854_CR46","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00213-003-1437-7","volume":"168","author":"E Quertemont","year":"2003","unstructured":"Quertemont E, Green HL, Grant KA (2003) Brain ethanol concentrations and ethanol discrimination in rats: effects of dose and time. Psychopharmacology 168:262\u2013270","journal-title":"Psychopharmacology"},{"key":"6854_CR47","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/13543784.2023.2276754","volume":"32","author":"A Ray","year":"2023","unstructured":"Ray A (2023) Retatrutide: a triple incretin receptor agonist for obesity management. Expert Opin Investig Drugs 32:1003\u20131008","journal-title":"Expert Opin Investig Drugs"},{"key":"6854_CR48","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3109\/10826084.2010.482427","volume":"45","author":"LA Ray","year":"2010","unstructured":"Ray LA, Mackillop J, Monti PM (2010) Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. Subst Use Misuse 45:1742\u20131765","journal-title":"Subst Use Misuse"},{"key":"6854_CR49","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/jpm12030454","volume":"12","author":"E Rentzeperi","year":"2022","unstructured":"Rentzeperi E, Pegiou S, Koufakis T et al (2022) Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: opportunities for a tailored approach to diabetes and obesity care. J Pers Med 12:454","journal-title":"J Pers Med"},{"key":"6854_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13293-016-0059-9","volume":"7","author":"JE Richard","year":"2016","unstructured":"Richard JE, Anderberg RH, L\u00f3pez-Ferreras L et al (2016) Sex and estrogens alter the action of glucagon-like peptide-1 on reward. Biol Sex Differ 7:1\u201316","journal-title":"Biol Sex Differ"},{"key":"6854_CR51","doi-asserted-by":"publisher","first-page":"50515","DOI":"10.4088\/JCP.23m15068","volume":"85","author":"JR Richards","year":"2023","unstructured":"Richards JR, Dorand MF, Royal K et al (2023) Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series. J Clin Psychiatry 85:50515","journal-title":"J Clin Psychiatry"},{"key":"6854_CR52","doi-asserted-by":"crossref","unstructured":"Samms RJ, Christe ME, Collins KA et al (2021) GIPR agonism mediates weight-independent insulin sensitization by Tirzepatide in obese mice. J Clin Investig 131(12)","DOI":"10.1172\/JCI146353"},{"key":"6854_CR53","doi-asserted-by":"publisher","first-page":"e61965","DOI":"10.1371\/journal.pone.0061965","volume":"8","author":"RH Shirazi","year":"2013","unstructured":"Shirazi RH, Dickson SL, Skibicka KP (2013) Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS ONE 8:e61965","journal-title":"PLoS ONE"},{"key":"6854_CR54","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/nprot.2006.167","volume":"1","author":"M Solinas","year":"2006","unstructured":"Solinas M, Panlilio LV, Justinova Z et al (2006) Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc 1:1194\u20131206","journal-title":"Nat Protoc"},{"key":"6854_CR55","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nn0605-697","volume":"8","author":"K Staley","year":"2005","unstructured":"Staley K, Scharfman H (2005) A woman\u2019s prerogative. Nat Neurosci 8:697\u2013699","journal-title":"Nat Neurosci"},{"key":"6854_CR56","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA) (2024) 2023 National Survey on Drug Use and Health (NSDUH) Annual National Report. U.S. Department of Health and Human Services. https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-annual-national-report"},{"key":"6854_CR57","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1038\/tp.2015.68","volume":"5","author":"P Suchankova","year":"2015","unstructured":"Suchankova P, Yan J, Schwandt M et al (2015) The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. Transl Psychiatry 5:e583\u2013e583","journal-title":"Transl Psychiatry"},{"key":"6854_CR58","doi-asserted-by":"crossref","unstructured":"Tetelbaun L, Mullally JA, Frishman WH (2024) The first triple agonist for antiobesity: Retatrutide. Cardiol Rev 10\u20131097","DOI":"10.1097\/CRD.0000000000000793"},{"key":"6854_CR59","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","volume":"236","author":"M Thomsen","year":"2019","unstructured":"Thomsen M, Holst JJ, Molander A et al (2019) Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring Vervet monkeys. Psychopharmacology 236:603\u2013611","journal-title":"Psychopharmacology"},{"key":"6854_CR60","doi-asserted-by":"publisher","first-page":"1092828","DOI":"10.3389\/fpsyt.2022.1092828","volume":"13","author":"M Tufvesson-Alm","year":"2023","unstructured":"Tufvesson-Alm M, Shevchouk OT, Jerlhag E (2023) Insight into the role of the gut-brain axis in alcohol-related responses: emphasis on GLP-1, amylin, and Ghrelin. Front Psychiatry 13:1092828","journal-title":"Front Psychiatry"},{"key":"6854_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.alcohol.2022.07.002","volume":"104","author":"RE Tyler","year":"2022","unstructured":"Tyler RE, Bluitt MN, Van Voorhies K et al (2022) Predator odor (TMT) exposure potentiates interoceptive sensitivity to alcohol and increases GABAergic gene expression in the anterior insular cortex and nucleus accumbens in male rats. Alcohol 104:1\u201311","journal-title":"Alcohol"},{"key":"6854_CR62","doi-asserted-by":"publisher","first-page":"173767","DOI":"10.1016\/j.pbb.2024.173767","volume":"239","author":"RE Tyler","year":"2024","unstructured":"Tyler RE, Van Voorhies K, Blough BE et al (2024) mGlu2 and mGlu3 receptor negative allosteric modulators attenuate the interoceptive effects of alcohol in male and female rats. Pharmacol Biochem Behav 239:173767","journal-title":"Pharmacol Biochem Behav"},{"key":"6854_CR63","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1111\/dom.15167","volume":"25","author":"S Urva","year":"2023","unstructured":"Urva S, O\u2019Farrell L, Du Y et al (2023) The novel GIP, GLP-1 and glucagon receptor agonist Retatrutide delays gastric emptying. Diabetes Obes Metabolism 25:2784\u20132788","journal-title":"Diabetes Obes Metabolism"},{"key":"6854_CR64","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/adb.12295","volume":"21","author":"D Vall\u00f6f","year":"2016","unstructured":"Vall\u00f6f D, Maccioni P, Colombo G et al (2016) The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol 21:422\u2013437","journal-title":"Addict Biol"},{"key":"6854_CR65","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA et al (2024) Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun 15:4548","journal-title":"Nat Commun"},{"key":"6854_CR66","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.14551","volume":"24","author":"S Wharton","year":"2022","unstructured":"Wharton S, Calanna S, Davies M et al (2022) Gastrointestinal tolerability of once-weekly semaglutide 2.4\u00a0mg in adults with overweight or obesity, and the relationship between Gastrointestinal adverse events and weight loss. Diabetes Obes Metab 24:94\u2013105","journal-title":"Diabetes Obes Metab"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06854-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:02:18Z","timestamp":1780722138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06854-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["6854"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06854-3","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were carried out in accordance with the NIH Guide for Care and Use of Laboratory Animals and institutional guidelines. All protocols were approved by the UNC Institutional Animal Care and Use Committee (IACUC). UNC-Chapel Hill is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}